Atlas›Domain IX · Biomedical, neuro & digital›Guide 105
Guide IX-105

Omega-3 and other nutrient augmentation

A 27 · L 68 · M 519 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the WFSBP and CANMAT Taskforce clinician guidelines on nutraceuticals and phytoceuticals (Sarris et al., 2022) as the main reference; the International Society for Nutritional Psychiatry Research (ISNPR) practice guidelines for omega-3 fatty acids in major depressive disorder (Guu et al., 2019) for omega-3; the CANMAT 2023 update for adult depression (Lam et al., 2024) as summarised in a secondary source [uncertain: not verified against the full CANMAT text]; US (FDA, NIH Office of Dietary Supplements, NCCIH) and UK (NHS Specialist Pharmacy Service) regulatory pages for status and safety.

Nutrient augmentation is not a psychotherapy. It means adding a nutrient-derived product (an EPA-predominant omega-3 preparation, folate or L-methylfolate, S-adenosyl-L-methionine (SAMe), vitamin D, zinc, N-acetylcysteine (NAC) and similar agents) to standard treatment, mostly to an antidepressant, on the theory that correcting a biological shortfall or acting on inflammation, one-carbon (methylation) metabolism or glutamate and oxidative pathways may lift response. The guidelines frame these agents as adjuncts within standard care, not replacements for it, especially in severe illness [source: Sarris et al., 2022; Guu et al., 2019]. Decisions to start, choose, stop or change any of them belong to the client and their prescriber, pharmacist or physician.

The psychotherapist's job is different: ask about supplements routinely, respond to clients who self-supplement without either endorsing or dismissing them, give balanced and attributed information, route medical questions and warning signs to the prescriber or pharmacist, support shared decision-making, and keep the psychological work going. This guide gives no doses, products, brands or formulations to use; where guidelines specify these, the guide says so and points to the prescriber. Diet-based approaches (for example ketogenic or metabolic therapy) are separate entries in this family and need medical supervision [synthesis].

2. Framework

There is no session protocol for psychotherapists; nutrient augmentation is woven into ongoing therapy. The working sequence below is [synthesis], built on the guidelines' own steps: confirm the diagnosis and physical health first, use measurement-based assessment, use agents as add-ons to standard treatment, monitor adverse effects, and review benefit [source: Guu et al., 2019; Sarris et al., 2022].

Phase A. Inventory (first sessions, then at every review). Goal: know everything the client takes (prescribed medicines, over-the-counter products, supplements, herbal products, powders, "stacks", fortified drinks) and why. Format: a few minutes in intake and at each formal review. Move on when the list is complete and shared (with consent) with the prescriber or GP.

Phase B. Medical review and referral. Goal: get any supplement use, or any wish to start one, in front of the person who can check diagnosis, physical health, interactions and labs. ISNPR advises a clinical interview to confirm the diagnosis, a check of physical conditions and measurement-based assessment before omega-3 is recommended [source: Guu et al., 2019]. Move on when the prescriber or pharmacist has reviewed the plan, or the client has made an informed choice not to involve them (document this).

Phase C. Shared decision support during a trial. Goal: the client understands evidence level, regulatory status and risks, and has agreed with the prescriber how long a trial lasts and how benefit will be judged. A CANMAT presenter suggests agreeing a defined trial period and criteria for judging benefit, as with psychotherapy or medication trials [source: Psychopharmacology Institute summary of CANMAT 2023; uncertain: secondary source]. Format: part of regular sessions. Move on when a trial plan exists.

Phase D. Monitoring and liaison. Goal: track mood with the same measure used at baseline; note and pass on side effects and warning signs (Section 4) to the prescriber. Format: brief check-in each session; formal measure at agreed intervals [synthesis]. Move on at the agreed review point.

Phase E. Review and integration. Goal: support the client to discuss outcome with the prescriber; process disappointment or attribution of change; keep psychological gains owned by the client. Return to Phase A whenever anything new is added.

3. Guiding principles

  • Adjunct, not replacement. Never present a nutrient as an alternative to evidence-based treatment of moderate or severe illness; the guidelines frame them as adjuncts [source: Sarris et al., 2022].
  • Stay in scope. The therapist does not recommend, dose, choose products or advise changes; every such question goes to the prescriber, physician or pharmacist [synthesis; consistent with the medical role in Guu et al., 2019].
  • Ask, because clients often do not tell. The taskforce notes that patients often do not disclose supplement and herbal use to their primary practitioner [source: Sarris et al., 2022]. Practical meaning: ask directly, every time medication is reviewed.
  • "Natural" does not mean safe. Many people wrongly assume natural products are safe, including in pregnancy [source: Sarris et al., 2022]. Practical meaning: treat supplements as active substances with risks and interactions.
  • Attribute, do not overclaim. Evidence levels differ by agent and disorder and guidelines disagree (Section 4). Practical meaning: name who says what ("the 2022 WFSBP-CANMAT taskforce rated…"), never "this works".
  • Regulatory status shapes what a label means. In the US, dietary supplements are not FDA-approved before sale and may not claim to treat disease [source: ODS, What You Need to Know]; in the UK, food supplements are regulated as food, with no pre-market proof of safety or efficacy [source: SPS, Understanding food supplements]. Practical meaning: a label or a "clinical grade" claim is not evidence.
  • Quality varies. Product standardisation, adulteration and contamination are significant concerns; ISNPR notes product quality may affect activity [source: Sarris et al., 2022; Guu et al., 2019]. Practical meaning: quality questions go to the pharmacist.
  • Bipolar disorder needs special caution. SAMe may worsen mania; omega-3 has not been shown to reduce mania [source: NCCIH SAMe; Sarris et al., 2022]. Practical meaning: screen for bipolarity and watch for activation.
  • Measure, do not guess. Use the baseline measure the team uses so benefit is judged, not assumed [source: Guu et al., 2019 on measurement-based assessment].
  • Respect autonomy. Clients may choose supplements; the aim is an informed, coordinated choice, not compliance with the therapist's view [synthesis].
  • Eating and food are sensitive. Supplement talk can feed restriction, "clean eating" rigidity or body-image concerns; screen for eating disorders and keep weight and diet targets out of therapy [synthesis].

[source for section: Sarris et al., 2022; Guu et al., 2019; ODS; SPS; NCCIH]

4. Intervention inventory

Part A describes, at a descriptive level only, how each agent is positioned by guidelines and regulators, so the therapist can talk about it accurately. Part B gives the therapist's own interventions. No doses, products, brands or formulations are recommended anywhere; where guidelines specify them, the prescriber holds that information.

How the guidelines rate the agents (for orientation, attributed). The 2022 WFSBP-CANMAT taskforce uses graded labels (Recommended, Provisionally Recommended, Weakly Recommended, Not Currently Recommended, Not Recommended) [source: Sarris et al., 2022]. CANMAT 2023 for adult depression uses lines of treatment and severity [source: Psychopharmacology Institute summary; uncertain: secondary source]. The two do not always agree, notably on omega-3 (below). When talking with clients, name the guideline and year.

A1. EPA-predominant omega-3 fatty acids (description)

  • Purpose and when it comes up: the most-researched nutrient adjunct in depression; clients often already take fish oil.
  • Guideline positions: WFSBP-CANMAT 2022: adjunctive use in major depression Recommended, monotherapy Not Currently Recommended; adjunctive in bipolar depression Weakly Recommended; schizophrenia Not Recommended (possible role in at-risk youth noted); ADHD Not Currently Recommended; not shown to attenuate mania [source: Sarris et al., 2022]. ISNPR 2019: use as an add-on to antidepressants, either started with a new antidepressant or added after inadequate response; pure EPA or EPA-predominant combinations considered effective (the guideline specifies a ratio and dose range, held by the prescriber); possible roles in perinatal depression, children, older adults and in people with raised BMI or inflammatory markers; possible prevention in high-risk groups needs larger trials [source: Guu et al., 2019; Medical Dialogues summary]. CANMAT 2023 lists omega-3 as third line, for mild depression only [source: Psychopharmacology Institute summary; uncertain: secondary source]. The 2021 Cochrane review found a small-to-modest effect below the threshold of clinical importance, with low to very low certainty [source: Appleton et al., 2021].
  • Regulatory status: as of October 2026 per NIH ODS and SPS, in the US most omega-3 products are dietary supplements with widely varying content; separate prescription omega-3 medicines exist and are described by NIH ODS in the context of triglyceride lowering [source: ODS omega-3 fact sheet]. None of the sources cited reports a psychiatric indication for any omega-3 medicine [uncertain: not verified in labelling]. UK: food supplements are regulated as food [source: SPS].
  • Risks to route to the prescriber or pharmacist: gastrointestinal and skin effects (ISNPR advises monitoring these and metabolic panels); fish hypersensitivity; at higher doses reduced platelet aggregation and longer bleeding time; caution with anticoagulants and before surgery; prescription-product labels advise periodic INR monitoring with anticoagulants; slightly increased atrial fibrillation risk with long-term high-dose use in people with or at high cardiovascular risk; oxidised products [source: Guu et al., 2019; ODS; Sarris et al., 2022].
  • Steps [synthesis]: (1) Ask whether the client takes fish oil or another omega-3 product, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Ask about anticoagulants, planned surgery and any bipolar history, and flag these. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "Guidelines differ on fish oil for depression. The 2022 international taskforce supports it as an add-on to an antidepressant; the Canadian 2023 update places it further down the list. It is worth asking your prescriber how it fits your plan, and checking with the pharmacist because of your blood thinner."
  • Watch for: unusual bruising or bleeding, nosebleeds, palpitations, gastrointestinal upset; client stopping an antidepressant in favour of fish oil; elevated mood in bipolar-spectrum clients (omega-3 does not protect against mania). Pass on to the prescriber.

A2. Folate and L-methylfolate (description)

  • Purpose and when it comes up: clients may have read about folate or "MTHFR" and methylation.
  • Guideline positions: WFSBP-CANMAT 2022: adjunctive L-methylfolate in major depression Provisionally Recommended, and as an adjunct mainly for negative symptoms in schizophrenia Provisionally Recommended; folic acid in depression Not Recommended; large synthetic folic acid intakes linked to a very slight increase in some cancers [source: Sarris et al., 2022]. CANMAT 2023: L-methylfolate second line as an adjunct in mild or moderate depression [source: Psychopharmacology Institute summary; uncertain: secondary source].
  • Regulatory status: as of October 2026 per the FDA medical-foods pages, in the US some L-methylfolate products are marketed as "medical foods" [uncertain: product marketing status not verified]. Under the FDA's 2023 FAQ, a medical food is formulated for use "under the supervision of a physician" for the dietary management of a disease with distinctive nutritional requirements; medical foods are not drugs, are not subject to drug requirements, do not need a prescription and may not carry an "Rx only" symbol; FDA keeps no comprehensive list of them [source: FDA medical foods page; FDA FAQ 3rd ed.]. Practical meaning: "medical food" or "prescription vitamin" does not mean FDA-approved for depression. UK equivalent category: foods for special medical purposes [source: SPS].
  • Risks to route: masking of vitamin B12 deficiency and interactions with anticonvulsants and other medicines are commonly cited [uncertain: not verified]; any genetic testing claims.
  • Steps [synthesis]: (1) Ask whether the client takes folate or L-methylfolate, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Ask whether genetic test results or "medical food" labels drove the choice, and clarify what the label means. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "Methylfolate is sometimes called a medical food. That label is a US food category, not an approval as an antidepressant. Your prescriber can tell you whether it makes sense for you and whether any blood tests are needed first."
  • Watch for: direct-to-consumer genetic test reports driving self-treatment; client confusion between folic acid and L-methylfolate; cost burden; changes in mood or sleep after starting.

A3. SAMe (S-adenosyl-L-methionine) (description)

  • Purpose and when it comes up: sold as a mood supplement.
  • Guideline positions: WFSBP-CANMAT 2022: depression monotherapy Not Currently Recommended, adjunctive Weakly Recommended; caution in bipolar disorder because of potential to induce mania; product instability noted [source: Sarris et al., 2022]. CANMAT 2023: third line as an adjunct in mild to moderate depression [source: Psychopharmacology Institute summary; uncertain: secondary source].
  • Regulatory status: as of October 2026 per NCCIH, sold as a dietary supplement in the US; known as ademetionine in Europe [source: NCCIH SAMe]. European medicinal status [uncertain: not verified].
  • Risks to route: NCCIH states people with bipolar disorder should not take SAMe for depression except under a provider's supervision because it may worsen mania; it may reduce the effect of levodopa; it might interact with antidepressants, L-tryptophan and St John's wort (serotonergic agents); safety in pregnancy is not established; theoretical concern in immunocompromised people; long-term safety data are limited (fact sheet last updated 2017) [source: NCCIH SAMe].
  • Steps [synthesis]: (1) Ask whether the client takes SAMe, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Ask about any history of elevated mood and about antidepressants or other serotonergic products, and flag these promptly. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "SAMe can interact with antidepressants, and in people with any history of high or unusually energetic moods it can tip things up. Before going further, could we bring this to your prescriber?"
  • Watch for: decreased need for sleep, pressured speech, irritability, impulsivity, racing thoughts (possible hypomania); agitation, tremor, sweating, confusion (possible serotonergic toxicity, an urgent medical matter [synthesis]).

A4. Vitamin D (description)

  • Purpose and when it comes up: clients often take vitamin D on their own or have read that low levels cause low mood.
  • Guideline positions: WFSBP-CANMAT 2022: depression Weakly Recommended (adjunctive or monotherapy); schizophrenia adjunct Not Recommended; ADHD adjunct Weakly Recommended; may be toxic at very large doses [source: Sarris et al., 2022].
  • Regulatory status: dietary or food supplement (US, UK), as of October 2026 per ODS and SPS [source: ODS; SPS].
  • Risks to route: very large intakes; whether testing of levels is indicated is a medical decision [synthesis].
  • Steps [synthesis]: (1) Ask whether the client takes vitamin D, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Leave any question of testing levels to the GP or prescriber. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "Vitamin D has weaker support for mood than many people expect. If you are wondering about your levels, your GP is the person to test and advise."
  • Watch for: high-dose self-treatment; using vitamin D instead of reviewing a worsening depression; seasonal pattern that may warrant a separate medical conversation about light therapy (another entry) [synthesis].

A5. Zinc (description)

  • Purpose and when it comes up: clients may take zinc alone or within multi-mineral products marketed for mood or immunity.
  • Guideline positions: WFSBP-CANMAT 2022: adjunctive in depression Provisionally Recommended; ADHD Not Currently Recommended; may cause nausea on an empty stomach; caution at higher doses [source: Sarris et al., 2022].
  • Regulatory status: dietary or food supplement, as of October 2026 per ODS and SPS [source: ODS; SPS].
  • Steps [synthesis]: (1) Ask whether the client takes zinc, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Ask about multi-mineral products that may stack the same nutrient. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "Zinc has some early support as an add-on, but it is not a stand-alone treatment, and more is not better. Check with the pharmacist how it sits with your other tablets."
  • Watch for: nausea; stacked multi-mineral products; interaction questions (route to pharmacist).

A6. N-acetylcysteine (NAC) (description)

  • Purpose and when it comes up: clients with OCD, compulsive habits or psychosis may have read about NAC online.
  • Guideline positions: WFSBP-CANMAT 2022: adjunctive in OCD Weakly Recommended; trichotillomania Not Currently Recommended; bipolar depression adjunct Not Currently Recommended; schizophrenia adjunct, mainly negative symptoms, Provisionally Recommended [source: Sarris et al., 2022].
  • Regulatory status: in the US, FDA concluded NAC is excluded from the dietary supplement definition because it was approved as a new drug before being marketed as a supplement; since August 2022 FDA has exercised enforcement discretion over certain products labelled as supplements, pending rulemaking or a petition decision; FDA's literature review entered peer review in November 2023 [source: FDA NAC update, checked October 2026]. Practical meaning: as of October 2026 per that FDA page, status is unsettled and may change.
  • Steps [synthesis]: (1) Ask whether the client takes NAC, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Check that it is not replacing an evidence-based psychological treatment such as exposure and response prevention. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "NAC has some support as an add-on for OCD in one international guideline, but it is a medical decision. Your psychiatrist can weigh it against the treatments with stronger evidence, like exposure and response prevention and the medicines you already know about."
  • Watch for: NAC replacing exposure and response prevention; gastrointestinal effects; use alongside other medicines (route to pharmacist) [synthesis].

A7. Other products clients commonly combine (description)

  • Purpose: clients who supplement often also take herbal or amino-acid products that interact with psychiatric medicines.
  • Key cautions as sources state them: St John's wort must not be combined with SSRIs or SNRIs (serotonin syndrome risk), induces several liver enzymes and P-gp affecting drugs such as warfarin, oral contraceptives and ciclosporin, causes photosensitivity and needs caution in bipolar disorder; tryptophan or 5-HTP carries a rare serotonin syndrome risk with antidepressants; kava should be avoided with liver problems, alcohol, benzodiazepines or other sedatives; ginkgo needs caution with blood thinners; probiotics in depression were rated Provisionally Recommended as an adjunct; a broad-spectrum micronutrient formula was Weakly Recommended for ADHD; creatine, inositol and magnesium were not recommended for depression [source: Sarris et al., 2022; ODS].
  • Steps [synthesis]: (1) Ask whether the client takes any herbal, amino-acid or blended product, which product and why, and note it as the client reports it. (2) Give the attributed guideline position above, as an add-on not a replacement. (3) Ask the client to bring the labels or photos of them. (4) Pass it on to the prescriber or pharmacist; do not recommend, dose or choose a product.
  • Example language (illustrative): "Could you bring every bottle, or photos of the labels, next time? Some of these interact with each other, and your pharmacist can check them in a few minutes."
  • Watch for: multi-ingredient "mood blends" with undisclosed contents; any serotonergic combination; contraceptive users taking St John's wort.

[source for Part A: Sarris et al., 2022; Guu et al., 2019; Appleton et al., 2021; ODS; NCCIH; FDA; SPS; CANMAT 2023 via secondary summary]

Part B. The psychotherapist's interventions

Unless a source is tagged, the procedures in Part B are [synthesis]: standard collaborative-care practice built around the guideline and regulator statements cited.

B1. Routine supplement inquiry

  • Purpose: close the disclosure gap the taskforce describes [source: Sarris et al., 2022]. Use at intake, at each review and whenever mood changes unexpectedly.
  • Steps: (1) Ask an open question that normalises use, naming categories (vitamins, fish oil, herbal, powders, gym products, teas, products bought online). (2) For each item record name as on the label, who suggested it, when started, reason, how the client judges its effect. Do not record or discuss doses as advice; note them only as the client reports, for the prescriber. (3) Ask whether the prescriber, GP and pharmacist know; ODS advises telling all health providers and keeping a written list [source: ODS, What You Need to Know]. (4) With consent, send the list to the prescriber or GP.
  • Example language (illustrative): "Lots of people take something extra for mood or energy: fish oil, vitamins, herbal things, powders. What are you taking at the moment, even occasionally?"
  • Watch for: shame or defensiveness (normalise); products bought from social-media sellers; recent additions around the time of a mood change; it is working when the list is complete and the prescriber has seen it.

B2. Responding to a client who self-supplements

  • Purpose: keep the alliance and safety without endorsing, dismissing or advising.
  • Steps: (1) Express curiosity about what the client hopes it will do. (2) Reflect the reasonable part (wanting more control, fewer side effects, a "natural" route). (3) Offer to share what guidelines say, with permission (B3). (4) Name the specific risks that apply to them (bipolar history, anticoagulants, pregnancy, serotonergic medicines, surgery) and route them (B4). (5) Make clear that whether to continue is their decision with the prescriber, not the therapist's.
  • Example language (illustrative): "It makes sense that you want something you feel in charge of. I am not the right person to say whether to keep taking it, but I can tell you what the main guidelines say, and help you raise it with Dr X so it is checked against your other medicines."
  • Watch for: client hearing disapproval and ceasing to disclose; client hearing approval and stopping prescribed medication; it is working when the client keeps telling you what they take and has raised it with the prescriber.

B3. Balanced psychoeducation without overclaiming

  • Purpose: give accurate, attributed information on evidence and status.
  • Steps: (1) Ask what the client has read. (2) Give three facts per agent: the guideline position with name and year (Part A), that it is an add-on rather than a replacement, and its regulatory status (supplement, medical food, or unsettled as with NAC in the US). (3) Note disagreement where it exists (omega-3: WFSBP-CANMAT 2022 vs CANMAT 2023 vs Cochrane 2021). (4) Explain that a supplement label may not claim to treat disease and that quality seals indicate testing, not safety or effectiveness [source: ODS]; in the UK, supplements need no pre-market proof of safety or efficacy and contents can vary between batches [source: SPS]. (5) Check understanding in the client's words.
  • Example language (illustrative): "The honest summary is: some of these have modest evidence as add-ons to an antidepressant, guidelines disagree on how much, and none replaces treatment for a serious depression. Your prescriber can say whether one fits you."
  • Watch for: your own enthusiasm or scepticism leaking in; clients reading "recommended" as "cure"; marketing claims ("clinically proven", "pharmaceutical grade", "doctor formulated"); it is working when the client can state the evidence level and who to ask.

B4. Referral and medical review

  • Purpose: get diagnosis, physical health, interactions and tests checked by the right professional. ISNPR asks for diagnostic confirmation, physical-health checks and measurement-based assessment before omega-3 is recommended [source: Guu et al., 2019].
  • Steps: (1) Identify triggers for referral: any supplement plus a psychiatric medicine; bipolar disorder or a family history of it; anticoagulant or antiplatelet use; planned surgery; pregnancy, breastfeeding or trying to conceive; child or adolescent client; older adult with multiple medicines; liver, kidney or heart disease; Parkinson's disease (SAMe and levodopa); immunocompromise [source: NCCIH; Sarris et al., 2022; ODS]. (2) Choose the route: prescriber for treatment decisions, community pharmacist for interactions and product quality, GP for testing. (3) With consent, write a short note: current list, reason for concern, observations, question asked. (4) Agree with the client who will make the contact and by when. (5) Follow up at the next session.
  • Example language (illustrative): "Because you take a blood thinner, this is exactly the kind of thing a pharmacist should check. Would you be happy for me to write a short note to your GP listing what you take, or would you rather raise it yourself this week?"
  • Watch for: urgent signs (Section 5); delay of a needed medical review; it is working when there is a documented answer from the prescriber or pharmacist.

B5. Supporting informed consent and shared decision-making

  • Purpose: help the client reach an informed choice with the prescriber; the CANMAT 2023 presenter describes CAM use as a collaborative decision [source: Psychopharmacology Institute summary; uncertain: secondary source].
  • Steps: (1) Help the client list their goals, worries, preferences, costs and what would count as benefit. (2) Prepare questions to take to the appointment: How strong is the evidence for me? Is this an add-on or a substitute? What interactions apply? What tests are needed? What side effects should I report? How long is the trial and how will we judge it? What would we do if it does not help? (3) Rehearse the conversation if the client is anxious. (4) Debrief after.
  • Example language (illustrative): "Let us write down three questions you want answered by your psychiatrist about this, and what result would tell you it is worth continuing."
  • Watch for: therapist steering the choice; client feeling dismissed by the prescriber (repair, see Section 5); it is working when the client can state what was decided and why.

B6. Agreeing a trial and measuring outcome

  • Purpose: replace impressions with data. ISNPR emphasises measurement-based assessment; a CANMAT presenter suggests an agreed trial period and criteria for benefit [source: Guu et al., 2019; Psychopharmacology Institute summary].
  • Steps: (1) Use the measure the team already uses (e.g. PHQ-9 or another validated scale) at baseline. (2) Record the start date of any new product and of any other change (therapy phase, medication, life events). (3) Repeat the measure at the interval agreed with the prescriber. (4) Share scores with the client and, with consent, the prescriber. (5) At review, discuss multiple explanations for change (therapy, time, medication, expectancy).
  • Example language (illustrative): "Let us take a snapshot today with the questionnaire you know, so that when you and Dr X review this, there is something to go on."
  • Watch for: several changes at once making attribution impossible (raise with prescriber); client discounting their own effort in therapy; it is working when the review is based on scores.

B7. Monitoring and passing on side effects and warning signs

  • Purpose: be an additional set of eyes between appointments.
  • Steps: (1) Ask briefly each session about new physical symptoms, sleep, energy and mood. (2) Use the agent-specific lists in Part A (bleeding, palpitations, gastrointestinal upset, nausea, skin effects; hypomanic signs; serotonergic signs). (3) Pass non-urgent observations to the prescriber within the agreed channel; urgent ones per Section 5. (4) Encourage the client to report adverse reactions: in the US to their provider or FDA's Safety Reporting Portal; in the UK, the SPS points to the Food Standards Agency [source: ODS; SPS]. (5) Document.
  • Example language (illustrative): "Since you started this, have you noticed anything new in your body: stomach, skin, bruising, heartbeat? And how has your sleep and energy been?"
  • Watch for: decreased sleep with increased energy (screen for hypomania); bruising; new anxiety or agitation; it is working when concerns reach the prescriber promptly.

B8. Adherence and ambivalence conversations (never advising a change)

  • Purpose: explore why a client prefers supplements to prescribed treatment, or is stopping either, without advising.
  • Steps: (1) Elicit both sides of the ambivalence (side effects, stigma, cost, identity, beliefs about "chemicals"). (2) Reflect values. (3) Name, without advising, that stopping prescribed medicine can carry risks and is something to plan with the prescriber. (4) Support the client to raise the concerns directly. (5) Keep the decision with the client and prescriber.
  • Example language (illustrative): "Part of you is tired of the side effects, and part of you remembers how bad things were. Whatever you decide, it would be safest to work it out with Dr X rather than change things on your own. What would you want to say to them?"
  • Watch for: abrupt stopping of an antidepressant or mood stabiliser (alert prescriber with consent); relapse signs; it is working when the client discusses changes before making them.

B9. Eating-disorder screening and caution

  • Purpose: supplement interest can sit within restrictive eating, orthorexic patterns or weight control.
  • Steps: (1) Screen briefly for eating-disorder features (restriction, bingeing, compensatory behaviour, weight and shape preoccupation) using the team's validated tool. (2) Ask whether supplements are used to replace meals, suppress appetite or "detox". (3) If positive, refer for eating-disorder assessment and medical review. (4) Do not discuss diet plans, calorie, macronutrient or weight targets. (5) Coordinate with the eating-disorder team.
  • Example language (illustrative): "Sometimes supplements become part of very strict rules around food. Is that something that has been happening for you?"
  • Watch for: rigid food rules, low weight, laxative or diuretic products in the list; it is working when risk has been assessed by the right service.

B10. Special populations

  • Purpose: flag groups needing prescriber input before any use.
  • Steps: (1) Pregnancy and breastfeeding: safety data are limited; omega-3 has the most perinatal evidence; SAMe safety in pregnancy not established; route to obstetric or perinatal psychiatric care [source: Sarris et al., 2022; NCCIH]. (2) Children and adolescents: route to the paediatric prescriber; parents may buy ADHD supplements; WFSBP-CANMAT positions differ by agent (Part A). (3) Bipolar disorder: SAMe mania risk; St John's wort caution; omega-3 does not prevent mania [source: Sarris et al., 2022; NCCIH]. (4) Older adults and people with medical illness or polypharmacy: pharmacist review.
  • Example language (illustrative): "Because you are pregnant, the safety of anything you take is a question for your midwife or perinatal team. Shall we put it on the list for your next appointment?"
  • Watch for: perinatal mood changes; hypomania; parental pressure; it is working when the relevant specialist has reviewed.

B11. Crisis and safety planning

  • Purpose: keep supplement trials from delaying care for worsening illness.
  • Steps: (1) Assess suicide risk using standard practice at baseline and when mood worsens. (2) Add to the safety plan: urgent contacts, the prescriber's number, and the agreement that worsening depression, suicidal thinking, mania signs or severe physical symptoms are reasons for urgent review, not for adding another product. (3) Lethal-means counselling covers safe storage and limited supplies of all medicines and supplements at home [synthesis].
  • Example language (illustrative): "If things get worse while you are trying this, that is a reason to call Dr X or the crisis line straight away, not to wait and see."
  • Watch for: "waiting for it to kick in" while deteriorating; it is working when the client can name what they would do.

B12. Integrating psychotherapy before, during and after

  • Purpose: keep the psychological work central. A CANMAT presenter notes that continuing or adding psychotherapy during a CAM trial causes no harm [source: Psychopharmacology Institute summary; uncertain: secondary source].
  • Steps: (1) Before: agree that therapy continues regardless. (2) During: continue the planned therapy; use the client's attributions as material (agency, hope, control). (3) After: review what helped, with the client owning their behavioural and cognitive changes; plan relapse prevention including when to seek medical review.
  • Example language (illustrative): "Whatever part the omega-3 played, you also got back to walking and seeing friends. Let us make sure those stay in your plan."
  • Watch for: magical attribution of all change to a product; disappointment when a supplement fails; it is working when the client has a relapse-prevention plan that does not depend on any single product.

5. Handling problems

The sources say little about therapy-process problems; the responses below are [synthesis] unless tagged.

  • Urgent physical or psychiatric warning signs. Signs of possible serotonin toxicity (agitation, confusion, sweating, tremor, muscle twitching, fever) after combining serotonergic products; significant bleeding; chest pain or palpitations; signs of mania or psychosis; suicidal intent. Response: stop the routine session agenda, follow the service's emergency procedure (emergency services, urgent prescriber contact, crisis team), and document. Do not advise on stopping or continuing any product; the medical team decides.
  • Client stops prescribed medication for a supplement. Explore reasons (B8), name that changes are safest planned with the prescriber, ask permission to inform the prescriber, and increase monitoring of relapse and discontinuation symptoms. If risk is high and consent is refused, follow your confidentiality and duty-of-care rules.
  • Client will not tell the prescriber. Explore the fear (being judged, being told to stop). Offer options: a pharmacist conversation, a joint letter, role-play. Record that the risks were discussed. Escalate without consent only where your professional rules allow for serious risk.
  • Prescriber dismisses the client's interest (rupture with the medical team). Validate the frustration, help the client re-present the question with the specific guideline and year (for example the 2022 WFSBP-CANMAT positions), and avoid taking sides. If the therapist disagrees with a medical decision, raise it professionally with the prescriber, not through the client.
  • Rupture with the therapist (client feels lectured). Acknowledge, return to curiosity, separate information from judgement, and restate the client's autonomy.
  • "Stuck" or non-response. Review the outcome measure; ISNPR suggests evaluating product quality in omega-3 non-responders, which is a prescriber or pharmacist task [source: Guu et al., 2019]. Revisit diagnosis, formulation and the psychological plan; avoid adding product after product.
  • Overwhelm and information overload. Clients flooded by online protocols, "stacks" or genetic reports: narrow to one question for the prescriber, limit research time, and treat compulsive health-information seeking as clinical material.
  • Belief that supplements are safe because natural. Use the taskforce's point that this belief is common and wrong, especially in pregnancy, with concrete interaction examples (St John's wort and contraceptives, SAMe and mania) [source: Sarris et al., 2022; NCCIH].
  • Cost and exploitation. Some clients spend heavily or are sold products by practitioners with a financial interest. Explore cost, encourage pharmacist advice, and note that US supplement labels carrying structure-function claims must state they have not been evaluated by FDA [source: ODS].
  • Regulatory confusion. Clients may believe a "medical food" or "prescription vitamin" is an approved antidepressant. Explain the US FDA medical-food definition and that medical foods are not drugs [source: FDA FAQ 3rd ed.]; for NAC, explain that its US status is unsettled [source: FDA NAC update]. Status changes; re-check before relying on it.
  • Eating-disorder signals. Pause supplement discussion, assess risk, refer (B9). Do not engage with diet plans or weight goals.
  • Therapist's own position. Therapists who are enthusiastic or sceptical about nutritional psychiatry risk overclaiming either way. Use attributed statements, stay within scope, and take uncertainty to supervision.
  • Bipolar or unclear diagnosis. Screen for past hypomania before any discussion of SAMe or St John's wort and share the screen with the prescriber [source: NCCIH; Sarris et al., 2022].
  • Gaps in this guide. Detailed EU and UK medicinal status of SAMe (ademetionine), current US marketing of L-methylfolate products and the full CANMAT 2023 text are [uncertain: not verified]; check them locally.

Sources

← Previous · IX-104Ketogenic and metabolic therapyNext · IX-106 →Lifestyle psychiatry